Florida's Full Faith & Credit State Brd of Ed Pub Ed Cap Outlay Rfdg Bnds Ser 2001D Rtd 'AA+' Aug 01

  • ID: 1751166
  • August 2001
  • Region: Florida
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) Aug. 14, 2001Standard & Poor's today assigned its double-'A'-plus rating to Florida's $275.445 million full faith and credit state board of education public education capital outlay refunding bonds series 2001D due June 1, 2019. The outlook is stable. In addition, Standard & Poor's affirmed its double-'A'-plus rating on the state's outstanding full faith and credit debt. The bonds are ultimately secured by the state's full faith and credit pledge. Debt service is payable in the first instance from a second-lien pledge on gross receipts tax revenues collected from providers of electric, natural gas, and telecommunications industries operating in the state. The taxes are constitutionally dedicated to pay debt service. Gross receipts tax revenues of $723...

Companies mentioned in this report are:
- Florida

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3


Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.